IL153908A0 - PHARMACEUTICAL COMPOSITIONS CONTAINING 2alpha-METHYL-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3 - Google Patents

PHARMACEUTICAL COMPOSITIONS CONTAINING 2alpha-METHYL-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3

Info

Publication number
IL153908A0
IL153908A0 IL15390801A IL15390801A IL153908A0 IL 153908 A0 IL153908 A0 IL 153908A0 IL 15390801 A IL15390801 A IL 15390801A IL 15390801 A IL15390801 A IL 15390801A IL 153908 A0 IL153908 A0 IL 153908A0
Authority
IL
Israel
Prior art keywords
compound
bone
2alpha
1alpha
dihydroxyvitamin
Prior art date
Application number
IL15390801A
Other languages
English (en)
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of IL153908A0 publication Critical patent/IL153908A0/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • B22D17/22—Dies; Die plates; Die supports; Cooling equipment for dies; Accessories for loosening and ejecting castings from dies
    • B22D17/2236—Equipment for loosening or ejecting castings from dies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • B22D17/22—Dies; Die plates; Die supports; Cooling equipment for dies; Accessories for loosening and ejecting castings from dies
    • B22D17/24—Accessories for locating and holding cores or inserts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mechanical Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15390801A 2000-07-14 2001-07-10 PHARMACEUTICAL COMPOSITIONS CONTAINING 2alpha-METHYL-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3 IL153908A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/616,778 US6306844B1 (en) 1997-03-17 2000-07-14 Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
PCT/US2001/021660 WO2002005824A1 (en) 2000-07-14 2001-07-10 USE OF 2α-METHYL-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH

Publications (1)

Publication Number Publication Date
IL153908A0 true IL153908A0 (en) 2003-07-31

Family

ID=24470903

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15390801A IL153908A0 (en) 2000-07-14 2001-07-10 PHARMACEUTICAL COMPOSITIONS CONTAINING 2alpha-METHYL-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3
IL153908A IL153908A (en) 2000-07-14 2003-01-13 Pharmaceutical preparations containing 2α - methyl - 19 - nur - (S) 20 - 1α, 25 - dihydroxyvitamin D3

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153908A IL153908A (en) 2000-07-14 2003-01-13 Pharmaceutical preparations containing 2α - methyl - 19 - nur - (S) 20 - 1α, 25 - dihydroxyvitamin D3

Country Status (16)

Country Link
US (4) US6306844B1 (enExample)
EP (1) EP1305030B1 (enExample)
JP (1) JP4955895B2 (enExample)
KR (1) KR100572958B1 (enExample)
CN (1) CN1250225C (enExample)
AT (1) ATE359796T1 (enExample)
AU (2) AU2001273303B8 (enExample)
BR (1) BR0112453A (enExample)
CA (1) CA2416187A1 (enExample)
DE (1) DE60127964T2 (enExample)
DK (1) DK1305030T3 (enExample)
ES (1) ES2286129T3 (enExample)
IL (2) IL153908A0 (enExample)
MX (1) MXPA03000405A (enExample)
NZ (1) NZ524018A (enExample)
WO (1) WO2002005824A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
BR0112454A (pt) * 2000-07-14 2003-07-29 Wisconsin Alumni Res Found Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de composto
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
HK1079766B (zh) * 2002-03-29 2007-05-25 威斯康星校友研究基金会 合成1α-羟基-2-亚甲基-19-去甲-高孕钙化醇的方法
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
EP1598360A4 (en) 2003-02-25 2010-04-07 Knc Lab Co Ltd NEW INTERMEDIATE PRODUCTS FOR THE SYNTHESIS OF VITAMIN D DERIVATIVES
AU2004273658A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation (Warf) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
DE602005020842D1 (de) * 2004-11-22 2010-06-02 Wisconsin Alumni Res Found 17,20(e)-dehydro-vitamin-d-analoga und deren verwendungen
WO2006096555A1 (en) * 2005-03-04 2006-09-14 Women And Infants Hospital Of Ri, Inc. Compositions and methods for cancer treatment
EP1877063A4 (en) * 2005-05-03 2009-11-04 Wisconsin Alumni Res Found 19,26,27-TRINOR-1ALPHA, 25-DIHYDROXYVITAMINE-D3 COMPOUNDS
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
MX2008012913A (es) * 2006-04-06 2009-03-06 Wisconsin Alumni Res Found 2-metilen-1a,25-dihidroxi-18,19,21-trinorvitamina d3 y sus usos.
MX2008012673A (es) * 2006-04-06 2008-10-15 Wisconsin Alumni Res Found Analogos de 2-metilen-1a-hidroxi-19, 21-dinorvitamina d3 y sus usos.
US8575136B2 (en) * 2006-04-06 2013-11-05 Wisconsin Alumni Research Foundation 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof
AU2007291005A1 (en) * 2006-04-06 2008-03-06 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2,or 3,2 heterocyclic ring
AU2007234717B2 (en) * 2006-04-06 2012-04-19 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
EP2021320A2 (en) 2006-04-06 2009-02-11 Wisconsin Alumni Research Foundation 2-substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof
ATE496885T1 (de) * 2006-04-10 2011-02-15 Wisconsin Alumni Res Found 1-alpha-hydroxy-2-(3'-hydroxypropyliden)-19-nor vitamin-d-verbindungen mit einer 1,1- dimethylpropyl-seitenkette
CA2651283A1 (en) * 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US8222236B2 (en) * 2008-07-10 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
JP5908402B2 (ja) * 2009-08-03 2016-04-26 ウィスコンシン・アルムニ・リサーチ・ファウンデーションＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 腎疾患の予防方法およびその症状を処置する方法
US8349818B2 (en) * 2009-10-21 2013-01-08 Wisconsin Alumni Research Foundation Method of preventing Type 1 diabetes
WO2011119610A2 (en) * 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
JP5931845B2 (ja) * 2010-03-23 2016-06-08 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー
US20130295083A1 (en) * 2012-05-02 2013-11-07 Wisconsin Alumni Research Foundation 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
MY172886A (en) 2012-06-29 2019-12-13 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
WO2017184262A1 (en) * 2016-04-18 2017-10-26 Wisconsin Alumni Research Foundation Use of 2amd and 2md to treat fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67153A (en) 1981-11-02 1986-12-31 Res Inst Medicine Chem Intermediates in the production of vitamin d analogues and method for their production
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
GB8904154D0 (en) 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
NZ232734A (en) 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
AU649057B2 (en) 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
ATE173401T1 (de) 1990-09-07 1998-12-15 Wisconsin Alumni Res Found Neue verwendung von 1-alpha-hydroxylierten-19-nor-vitamin-d-verbind ngen zur behandlung von psoriasis
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
AU650751B2 (en) 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
JP2898882B2 (ja) 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
WO1996001811A1 (en) 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity

Also Published As

Publication number Publication date
US6939868B2 (en) 2005-09-06
ES2286129T3 (es) 2007-12-01
EP1305030B1 (en) 2007-04-18
CN1501803A (zh) 2004-06-02
US20020151528A1 (en) 2002-10-17
AU2001273303B2 (en) 2006-02-02
AU2001273303B8 (en) 2006-03-09
NZ524018A (en) 2006-06-30
US20040072804A1 (en) 2004-04-15
IL153908A (en) 2009-08-03
MXPA03000405A (es) 2003-06-06
BR0112453A (pt) 2003-08-19
KR20030016402A (ko) 2003-02-26
US20060003973A1 (en) 2006-01-05
HK1066487A1 (en) 2005-03-24
US6306844B1 (en) 2001-10-23
KR100572958B1 (ko) 2006-04-24
JP4955895B2 (ja) 2012-06-20
DE60127964T2 (de) 2008-01-17
AU7330301A (en) 2002-01-30
DE60127964D1 (de) 2007-05-31
WO2002005824A1 (en) 2002-01-24
DK1305030T3 (da) 2007-09-17
EP1305030A1 (en) 2003-05-02
ATE359796T1 (de) 2007-05-15
CN1250225C (zh) 2006-04-12
CA2416187A1 (en) 2002-01-24
JP2004509853A (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
AU7330301A (en) Use of 2alpha-methyl-19-nor-20(s)-1alpha,25-dihydroxyvitamin D<sub>3</sub> to increase bone strength
MXPA03000406A (es) Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
IL164688A0 (en) Pharmaceutical compositions containing 1?-hydroxy-2-methyl-19-nor-vitamin D3 compounds
MXPA02009590A (es) Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.
MY146504A (en) 2-propylidene-19-nor-vitamin d compounds
Van Lieshout et al. Bone graft substitutes and bone morphogenetic proteins for osteoporotic fractures: what is the evidence?
AR004400A1 (es) Un acido nucleico aislado que codifica un polipeptido comprendiendo por lo menos una de las actividades de la osteoprotegerina (opc), polipeptidos,derivados de dichos polipeptidos, multimeros, vectores, celulas huesped, procedimiento para producir la osteoprotegerina, anticuerpos, metodos de deteccion, composiciones farmaceuticas y usos
BR0308355A (pt) Composto ou um sal farmaceuticamente aceitável ou um seu enanciÈmero, métodos para modular uma função mediada pelo receptor de androgênio em um mamìfero em necessidade de tal modulação, para ativar a função do receptor de androgênio em um mamìfero em necessidade de tal ativação, para tratar uma condição em um mamìfero, e para tratar osteoporose em um mamìfero em sua necessidade, composição farmacêutica, métodos para aumentar a densidade mineral óssea em um mamìfero em necessidade disto, para reduzir o risco de fraturas vertebrais ou não vertebrais em um mamìfero em necessidade disto, e para produzir um marcador de modificação óssea em um mamìfero em necessidade disto, processo para produzir uma composição farmacêutica, e, método para tratar ou prevenir uma condição artrìtica em um mamìfero em necessidade disto
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
ATE253046T1 (de) 2-alkyl-19-nor-vitamin d-verbindungen
EP1656157A4 (en) 2-METHYLENE-19-NOR-VITAMIN D2 COMPOUNDS
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
ATE534623T1 (de) 2-alkyliden-18,19-dinor-vitamin-d-verbindungen
NZ535843A (en) Use of carbon-2-modified-19-nor-vitamin D analogs to induce the formation of new bone
MX9800801A (es) Proteina mp52 arg humana.
In et al. Cruciate-retaining stemmed total knee arthroplasty for supracondylar-intercondylar femoral fractures in elderly patients: a report of three cases
Harnroongroj et al. Reconstruction of the pelvic brim and its role in the reduction accuracy of displaced T-shaped acetabular fracture
GB0026114D0 (en) New use
ATE350043T1 (de) 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
Evans et al. Technique for costochondral graft placement
AU2002235991A1 (en) Use of the g-csf as adjuvant treatment in connective tissue recontruction
WO1997023612A3 (de) Zielgerichtete verbindungen mit knorpel- und/oder knocheninduzierender aktivität
Vignesh et al. An illustrative case report emphasizing the biological plating of a comminuted intra-articular fracture
Orwoll Gender differences in the skeleton: osteoporosis
Jupiter Fractures About the Elbow